Be Familiar With the Latest Oral Multiple Sclerosis Meds

November 2020

You’ll hear about a flurry of new ORAL meds to treat multiple sclerosis (MS)...such as Mayzent, Vumerity, and Zeposia.

Expect patients with relapsing-remitting MS to usually start treatment right away...to reduce flares and slow progression.

We’re used to seeing the injectables (Avonex, Copaxone, etc) first-line. Or patients with more severe disease may jump right to a monoclonal antibody IV infusion (Lemtrada, Tysabri, etc).

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote